Key Highlights
- Hims & Hers Health (NYSE:HIMS) closed at USD 22.98 on November 9, 2026, down 11.77% from USD 26.00 ahead of its after-close report, then touched USD 20.63 in extended trading.
- Third-quarter Revenue rose 49% to USD 890.4 million, in line with guidance of USD 880 million to USD 900 million, but the company swung to a net loss of USD 33.0 million, or USD 0.14 per share.
- Subscribers fell by 103,000 from the prior quarter to 2.79 million, the first sequential decline in at least four years, although they were still up 13% from a year earlier.
- The company tightened 2026 revenue guidance to USD 3.13 billion to USD 3.15 billion, below the prior midpoint, and cut adjusted EBITDA guidance to USD 257 million to USD 277 million, its third reduction this year.
What Went Wrong
The shares fell sharply during the regular session on November 9, before the results were released at 4:05 PM ET, and no single trigger for that move was confirmed. The report then deepened the losses. Gross Margin fell to 57% from 74% a year earlier, because weight loss products cost more to source, pack and ship than the hair, skin and sexual health products on which the Business was built. Cost of revenue more than doubled to USD 381.2 million. Adjusted EBITDA rose only slightly to USD 82.4 million, and the margin fell to 9% from 13%. Free Cash Flow dropped to USD 26.0 million from USD 79.4 million, and Operating Cash Flow was flattered by USD 433.3 million of receivables sold to a bank. The subscriber decline worried investors most, since recurring subscriptions are the core of the growth story and of the valuation multiple the market has paid.
The Weight Loss Pivot and International Growth
Much of the revenue growth came from new sources. Eucalyptus, an Australian online health company acquired in June 2026, contributed about 46% of the year-on-year revenue increase and roughly 15% of quarterly revenue. International revenue rose 321% to USD 233.3 million, while US revenue grew 21% to USD 657.1 million, led by the Hers Brand in weight loss and skin care. Monthly revenue per subscriber climbed 30% to USD 105 as customers shifted toward higher-priced weight loss treatments. In March the company moved its US weight loss offering toward branded GLP-1 drugs, and on November 6 it announced an agreement to offer Lilly's Zepbound from USD 299 a month on a self-pay basis. Chief financial officer Yemi Okupe said the company was "intentionally pacing Marketing spend ahead of several planned expansions to our platform in the fourth quarter."
Risks and What to Watch
The outlook now leaves little room for error. Fourth-quarter guidance calls for revenue of USD 875 million to USD 895 million and adjusted EBITDA of USD 70 million to USD 90 million, so annual profit expectations have fallen sharply from the USD 300 million to USD 375 million range set in February. Branded GLP-1 margins are structurally lower, and competition in direct-to-consumer weight loss is intense. Regulatory Risk remains: a lawsuit filed by the Federal Trade Commission in July carries an accrual of about USD 60 million, with a hearing set for January 14, 2027. The company also carries USD 1.37 billion of convertible notes. Investors will watch whether the planned fourth-quarter platform launches reverse the subscriber decline and whether margins stabilise as the product mix settles.
Where Things Stand
Hims & Hers fell 11.77% in the November 9 session and extended losses after hours because a third-quarter loss, a sharp gross margin decline, the first sequential subscriber drop and a third cut to 2026 profit guidance outweighed 49% revenue growth. The shift into branded weight loss drugs and international markets is lifting sales but squeezing margins. Fourth-quarter subscriber trends will show whether the strategy can restore growth.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...